• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶型纤溶酶原激活物受体是乳腺癌的一种新型预后因素。

Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.

作者信息

Kim S J, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M, Takai S I

机构信息

Department of Surgical Oncology, Osaka University Medical School, Japan.

出版信息

Anticancer Res. 1997 Mar-Apr;17(2B):1373-8.

PMID:9137501
Abstract

BACKGROUND

There have been many reports that the u-PA system plays an important role in cancer invasion and metastasis. The binding of u-PA to its specific cell-surface receptor, u-PAR, is necessary for the activation of u-PA system. The aim of this study is to evaluate the role and the prognostic value of u-PAR in cancer invasion and metastasis.

PATIENTS AND METHODS

u-PAR expression in 104 breast cancers was investigated immunohistochemically using a monoclonal antibody against u-PAR.

RESULTS

u-PAR expression was mainly observed both on cancer cells and stromal cells. Patients with high u-PAR expression in cancer cells or stromal cells had a high relapse rate compared with patients with low u-PAR expression by the Kaplan-Meier method (p = 0.035 and 0.011, respectively). In uni- and multivariate analysis, u-PAR expression in stromal cells was significantly correlated with relapse (p = 0.017 and 0.043, respectively).

CONCLUSIONS

This study has shown that not only cancer cells but also stromal cells have an important roles in breast cancer invasion and metastasis, and that u-PAR expression in cancer cells and stromal cells might be a novel prognostic factor in breast cancer.

摘要

背景

已有许多报道称尿激酶型纤溶酶原激活物(u-PA)系统在癌症侵袭和转移中起重要作用。u-PA与其特异性细胞表面受体u-PAR的结合是u-PA系统激活所必需的。本研究的目的是评估u-PAR在癌症侵袭和转移中的作用及预后价值。

患者与方法

使用抗u-PAR单克隆抗体,通过免疫组织化学方法研究104例乳腺癌中u-PAR的表达情况。

结果

u-PAR表达主要见于癌细胞和基质细胞。采用Kaplan-Meier法分析,癌细胞或基质细胞中u-PAR高表达的患者与u-PAR低表达的患者相比,复发率更高(分别为p = 0.035和0.011)。在单因素和多因素分析中,基质细胞中u-PAR表达与复发显著相关(分别为p = 0.017和0.043)。

结论

本研究表明,不仅癌细胞,而且基质细胞在乳腺癌侵袭和转移中都起重要作用,并且癌细胞和基质细胞中u-PAR的表达可能是乳腺癌一种新的预后因素。

相似文献

1
Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.尿激酶型纤溶酶原激活物受体是乳腺癌的一种新型预后因素。
Anticancer Res. 1997 Mar-Apr;17(2B):1373-8.
2
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.尿激酶型纤溶酶原激活物(PA)、1型PA抑制剂及组织型PA抗原水平对淋巴结阴性乳腺癌的预后影响:一项多中心前瞻性研究
Clin Cancer Res. 1998 Jan;4(1):177-82.
3
Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.尿激酶系统在胃癌中的表达:独立患者系列中的预后影响以及术前活检和肠化生标本中预测价值的首个证据。
Cancer. 2006 Mar 1;106(5):1026-35. doi: 10.1002/cncr.21682.
4
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.尿激酶型纤溶酶原激活物受体在乳腺癌中的预后意义
Clin Cancer Res. 1995 Oct;1(10):1079-87.
5
Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.在切除的结直肠癌中,激活蛋白-1家族成员、Sp1和一种与尿激酶受体基因不同区域结合的激活蛋白-2α相关因子的联合分析。
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8538-48. doi: 10.1158/1078-0432.CCR-05-0786.
6
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.2780例乳腺癌患者纤溶酶原激活物的尿激酶系统与预后
Cancer Res. 2000 Feb 1;60(3):636-43.
7
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.基质金属蛋白酶(MMP)-2和MMP-9在乳腺癌中的表达:特别提及激活蛋白-2、人表皮生长因子受体2(HER2)及预后
Clin Cancer Res. 2004 Nov 15;10(22):7621-8. doi: 10.1158/1078-0432.CCR-04-1061.
8
Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.乙醇诱导培养的人内皮细胞中尿激酶受体上调。
Alcohol Clin Exp Res. 2001 Feb;25(2):163-70.
9
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.尿激酶受体在浸润性乳腺癌中表达,但在正常乳腺组织中不表达。
Cancer Res. 1994 Feb 15;54(4):861-6.
10
Preoperative u-PAR gene expression in bone marrow indicates the potential power of recurrence in breast cancer cases.骨髓中术前尿激酶型纤溶酶原激活物受体(u-PAR)基因表达提示乳腺癌病例的复发潜能。
Ann Surg Oncol. 2009 Jul;16(7):2035-41. doi: 10.1245/s10434-009-0465-x. Epub 2009 Apr 30.

引用本文的文献

1
Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.乳腺癌肿瘤的粗针活检会增加小鼠模型中的远处转移。
Neoplasia. 2014 Nov 20;16(11):950-60. doi: 10.1016/j.neo.2014.09.004. eCollection 2014 Nov.
2
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.肿瘤相关基质细胞中尿激酶型纤溶酶原激活物受体(uPAR)的表达与结直肠癌患者预后相关:一项组织芯片研究
BMC Cancer. 2014 Apr 17;14:269. doi: 10.1186/1471-2407-14-269.
3
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
肢体原发性黑色素瘤中组织型纤溶酶原激活剂(tPA)的高表达与良好预后相关。
Br J Cancer. 2000 Nov;83(10):1351-9. doi: 10.1054/bjoc.2000.1460.
4
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.尿激酶型纤溶酶原激活剂(uPA)、尿激酶型纤溶酶原激活剂受体(uPAR)和纤溶酶原激活物抑制剂-1(PAI-1)在乳腺癌中的免疫组化表达。成纤维细胞表达与肿瘤病理学密切相关。
Am J Pathol. 2000 Oct;157(4):1219-27. doi: 10.1016/S0002-9440(10)64637-8.